|
시장보고서
상품코드
2126615
호흡기질환 치료 시장 : 약물 계열별, 용도별, 투여 경로별, 유통 채널별, 지역별Respiratory Disease Treatment Market, By Drug Class, By Application, By Route of Administration, By Distribution Channel, By Geography |
||||||
호흡기질환 치료 시장은 2026년에 1,009억 450만 달러 규모에 달할 것으로 추정되며, 2033년까지 1,937억 6,880만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 9.8%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 1,009억 450만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간의 CAGR: | 9.80% | 2033년 시장 규모 예측: | 1,937억 6,880만 달러 |
천식, 만성 폐쇄성 폐질환(COPD), 호흡기 감염증, 폐섬유증, 기타 만성 폐질환 등의 호흡기질환은 전 세계적으로 큰 의료 부담을 초래하고 있습니다. 전 세계 호흡기질환 치료 시장에는 증상 관리, 악화 예방, 폐 기능 개선을 목적으로 하는 흡입제, 기관지확장제, 코르티코스테로이드, 생물학적 제제, 항생제, 기타 표적 치료 등 폭넓은 치료 옵션이 포함되어 있습니다.
세계 호흡기질환 치료 시장은 만성 호흡기질환 유병률의 증가, 인구 고령화, 대기 오염의 심화, 그리고 흡입 기술 및 전문 치료법의 발전에 의해 형성되고 있습니다. 복합 제제, 생물학적 제제, 스마트 흡입기 및 새로운 호흡기 치료법의 채택이 확대됨에 따라 치료 선택지는 계속해서 넓어지고 있습니다. 한편, 진단 기술의 향상과 질환에 대한 인식 제고로 인해 선진국 및 신흥국의 헬스케어 시장에서 더 조기적이고 지속적인 치료가 촉진되고 있습니다.
시장 역학
세계 호흡기질환 치료 시장은 천식 및 만성 폐쇄성 폐질환(COPD)을 비롯한 만성 호흡기질환의 유병률 증가와 대기 오염 및 담배 연기에 대한 노출 증가에 의해 주도되고 있습니다. 약물전달 기술의 발전에 힘입어 흡입 요법, 병용요법, 생물학적 제제의 채택이 확대되면서 전 세계적으로 질환 관리가 개선되고 치료 선택지가 늘어나고 있습니다.
그러나 고도의 호흡기 치료에 드는 높은 비용, 개발도상국에서 전문적인 치료법을 이용하기 어려운 점, 환자의 복약 순응도 및 흡입기 올바른 사용과 관련된 문제 등의 요인으로 인해 호흡기질환 치료 시장의 성장은 제한되고 있습니다. 그럼에도 불구하고, 새로운 생물학적 제제, 표적 치료, 차세대 흡입기, 그리고 의료 서비스가 충분히 제공되지 않는 환자층을 위한 호흡기 치료에 대한 투자 확대는 전 세계 호흡기질환 치료 시장에 새로운 기회를 가져다줄 것입니다.
본 조사의 주요 특징
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 밝히고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 해설하고 있습니다.
- 또한, 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 조사에서는 다음 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적 및 전략)를 바탕으로 전 세계 호흡기질환 치료 시장의 주요 기업들을 분석하고 있습니다.
- 본 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 기반한 의사결정을 내릴 수 있게 됩니다.
- 본 ‘전 세계 호흡기질환 치료 시장’ 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 전 세계 호흡기질환 치료 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 원활한 의사결정을 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 호흡기질환 치료 시장 : 약물 계열별, 2021-2033년
제5장 세계의 호흡기질환 치료 시장 : 용도별, 2021-2033년
제6장 세계의 호흡기질환 치료 시장 : 투여 경로별, 2021-2033년
제7장 세계의 호흡기질환 치료 시장 : 유통 채널별, 2021-2033년
제8장 세계의 호흡기질환 치료 시장 : 지역별, 2021-2033년
제9장 경쟁 구도
제10장 애널리스트의 제안
제11장 참고문헌 및 조사 방법
KSM 26.09.10Respiratory Disease Treatment Market is estimated to be valued at USD 100,904.5 Mn in 2026 and is expected to reach USD 193,768.8 Mn by 2033, growing at a compound annual growth rate (CAGR) of 9.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 100,904.5 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 9.80% | 2033 Value Projection: | USD 193,768.8 Mn |
Respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), respiratory infections, pulmonary fibrosis and other chronic pulmonary disorders constitute a substantial worldwide healthcare burden. The global respiratory disease treatment market includes a range of treatment options such as inhaled medicines, bronchodilators, corticosteroids, biologics, antibiotics and other targeted treatments used for symptom control, prevention of exacerbations and improvement of lung function.
The global respiratory disease treatment market is being shaped by the increased prevalence of chronic respiratory diseases, aging populations, rising air pollution and advances in inhalation technologies and specialized therapies. The growing adoption of combination medicines, biologic treatments, smart inhalers and novel respiratory therapies continues to expand treatment options, while improved diagnosis and disease awareness support earlier and more sustained treatment in developed and emerging healthcare markets.
Market Dynamics
The global respiratory disease treatment market is driven by growing prevalence of chronic respiratory diseases including asthma and chronic obstructive pulmonary disease (COPD), and the increasing exposure to air pollution and tobacco smoke. The rising adoption of inhaled therapies, combination treatments, and biologics, driven by advances in drug-delivery technologies, are improving disease management and increasing treatment options globally.
However, the growth of respiratory disease treatment market is limited by factors such as high cost of advanced respiratory therapies, lack of availability of specialized therapies in developing economies and issues related to patient adherence and correct inhaler use. Nevertheless, greater investment in new biologics, targeted treatments, next generation inhalers and respiratory therapies for unserved patient populations will offer opportunities in the global respiratory disease treatment market.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global respiratory disease treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include GSK plc, AstraZeneca PLC, Boehringer Ingelheim International GmbH, Sanofi, Novartis AG, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Pfizer Inc., and Regeneron Pharmaceuticals, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global respiratory disease treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global respiratory disease treatment market
Market Segmentation
- Drug Class Insights (Revenue, USD Mn, 2021 - 2033)
- Corticosteroids
- Bronchodilators
- Antihistamines
- Leukotriene Receptor Antagonists
- Antivirals
- Others
- Application Insights (Revenue, USD Mn, 2021 - 2033)
- Chronic Obstructive Pulmonary Disease (COPD)
- Asthma
- Acute Respiratory Infections
- Others
- Route of Administration Insights (Revenue, USD Mn, 2021 - 2033)
- Oral
- Nasal
- Parenteral
- Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- GSK plc
- AstraZeneca PLC
- Boehringer Ingelheim International GmbH
- Sanofi
- Novartis AG
- F. Hoffmann-La Roche Ltd
- Teva Pharmaceutical Industries Ltd.
- Merck & Co., Inc.
- Pfizer Inc.
- Regeneron Pharmaceuticals, Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Respiratory Disease Treatment Market, By Drug Class
- Global Respiratory Disease Treatment Market, By Application
- Global Respiratory Disease Treatment Market, By Route of Administration
- Global Respiratory Disease Treatment Market, By Distribution Channel
- Global Respiratory Disease Treatment Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Regulatory Scenario
- Industry Trends
4. Global Respiratory Disease Treatment Market, By Drug Class, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Bronchodilators
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Antihistamines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Leukotriene Receptor Antagonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Antivirals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
5. Global Respiratory Disease Treatment Market, By Application, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Chronic Obstructive Pulmonary Disease (COPD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Asthma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Acute Respiratory Infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
6. Global Respiratory Disease Treatment Market, By Route of Administration, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Nasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
7. Global Respiratory Disease Treatment Market, By Distribution Channel, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
8. Global Respiratory Disease Treatment Market, By Region, 2021 - 2033, Value (USD Mn)
- Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel,2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel,2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel,2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel,2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel,2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel,2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
- South Africa
- North Africa
- Central Africa
9. Competitive Landscape
- Company Profile
- GSK plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Boehringer Ingelheim International GmbH
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- F. Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Regeneron Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GSK plc
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us
